CLICKHERETO DOWNLOAD
NEnglJMed;DOI:/NEJMoaOlderpatientswithacutemyeloidleukemia(AML)haveadismalprognosis,evenaftertreatmentwithahypomethylatingagent Azacitidineandvenetoclaxinpreviouslyuntreatedacutemyeloidleukemia.digoxin,dabigatran,everolimus,sirolimus)withvenetoclaxshouldbeavoided.* VenetoclaxdoseisadjustedduetointeractionwithazoleantifungalprophylaxisVenetoclaxisaP-gp,BCRPandOATP1B1inhibitorinvitroThecombinationof azacitidine,venetoclax,andgilteritinibresultedinhighratesofCR/CRi,deepFLT3molecularresponses,andencouragingsurvivalinnewly1dayago Atyears fromdiagnosis,hehadasecondrelapseofAMLandwasinducedwithfludarabine,cytarabineandunspecifiedgranulocyte-colonystimulationfactorin combinationwithazacitidine,ConclusionAzacitidineaddedtovenetoclaxhadpromisingefficacyinatreatmentnaïvesubjectswithacutemyeloidleukemia (AML)SecondaryObjectives:ToevaluateifvenetoclaxincombinationwithazacitidinewillimprovetherateofCRToevaluateifvenetoclaxincombinationwith azacitidinewillimprovetherateofCRandcompleteremissionwithpartialhematologicrecoveryrate(CRh)IthasbeenoneyearsincetheU.S.FoodandDrug Administrationgrantedacceleratedapprovaltovenetoclaxincombinationwithazacitidineoritabine,orlow-dosecytarabineforthetreatmentofnewlydiagnosed acutemyeloidleukemia(AML)inolderpatients(>years)orpatientswithcomorbiditiesthatprecludedtheuseofintensiveinductThepurposeofthisstudywasto evaluate,fromaCanadianperspective,theeconomicimpactofvenetoclaxincombinationwithazacitidine(Ven+Aza)forthetreatmentofpatientswithnewly diagnosedAMLwhoareyearsorolderorwhohavecomorbiditiesthatprecludeusingICCo-administrationofnarrowtherapeuticindexP-gp,orBCRP substrates(egIfanarrowtherapeuticindexP-gporBCRPsubstratemustbeused,itshouldbeusedwithcautionProtocolfor:DiNardoCD,JonasBA, PullarkatV,etalHeWewouldliketoshowyouadescriptionherebutthesitewon’tallowusStartposaconazolevoriconazole(strongCYP3Ainhibitor)on dayVENETOCLAX*mgPOonDay1,mgPOonDay2,mgPOonDay3,thenmgPOoncedailyonfromDayonwards.Takewithorafterameal.azacitidine–venetoclaxcombinationregimenascomparedwithacontrolregimenofazacitidineandplaceboinpreviouslyuntreatedpatientswithAMLwhowereineligibleThe combinationofvenetoclax(ven)andazacitidine(aza)hasresultedinhighresponseratesintheupfronttreatmentofAMLinpatientsage>andpatientsunfitfor intensiveBackground:Venetoclax(Ven),ahighlyselectiveBCLinhibitor,combinedwithhypomethylatingagents(HMAs)azacitidine(Aza)oritabine()is approvedfor1SupplementalAppendixVenetoclaxandAzacitidineImprovesRemissionRatesandOverallSurvivalinPatientswithTreatment-naïveAcute MyeloidLeukemiaIneligibleforVENCLEXTAisaprescriptionmedicineused:totreatadultswithchroniclymphocyticleukemia(CLL)orsmalllymphocytic lymphoma(SLL)